PoLyglycolic Acid Felt reiNforcEmenT of the PancreaticoJejunostomy (PLANET-PJ Trial)

NCT03331718 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 514

Last updated 2026-05-05

No results posted yet for this study

Summary

The polyglycolic acid (PGA) felt is a felt-like absorbable suture reinforcing material. The pancreatojejunostomy aimed at reducing POPF is not established at present. We devised a new method using doubly PGA felt. This study is a multicenter, randomized phase III trial between Japan and Korea to verify the usefulness of this double coating of PGA felt.

Conditions

  • Disease of Pancreatic or Periampullary Lesions

Interventions

DRUG

PGA felt reinforcement

During pancreaticojejunostomy, 1) a 0.3 mm thick PGA felt (Neoveil®, Gunze, Japan) is pasted on the ventral side and the dorsal side of pancreatic parenchyma, through which suture between pancreatic parenchyma and jejunum is performed. 2) Before abdominal closure (after completion of all reconstruction, after washing in the abdominal cavity), a 0.15 mm thick PGA felt is further covered around the anastomotic site and fibrin glue is sprayed.

Sponsors & Collaborators

  • Seoul National University Hospital

    collaborator OTHER
  • Kansai Medical University

    collaborator OTHER
  • Kumamoto University

    collaborator OTHER
  • Nagoya University

    collaborator OTHER
  • Nara Medical University

    collaborator OTHER
  • Osaka City University

    collaborator OTHER
  • Osaka University

    collaborator OTHER
  • Shiga Medical University

    collaborator UNKNOWN
  • Shimane University

    collaborator UNKNOWN
  • Tokyo Medical and Dental University

    collaborator OTHER
  • Tokyo Medical University

    collaborator OTHER
  • Wakayama Medical University

    collaborator OTHER
  • Gangnam Severance Hospital

    collaborator OTHER
  • National Cancer Center, Korea

    collaborator OTHER_GOV
  • Samsung Medical Center

    collaborator OTHER
  • Seoul National University Bundang Hospital

    collaborator OTHER
  • Severance Hospital

    collaborator OTHER
  • University of Toyama

    lead OTHER

Principal Investigators

  • Tsutomu Fujii, MD, PhD · University of Toyama

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-10
Primary Completion
2021-12-31
Completion
2022-01-31

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03331718 on ClinicalTrials.gov